The viral vector market became highly active after the launch of a number of Advanced Therapy Medicinal Products (ATMPs). Based on the number of cases in clinical trials and its success rate to date of this writing, we can likely anticipate a cascade of FDA-approved products within years.
The complexity of viral particles remains one of the biggest hurdles in the development process. In this note, the upstream process of analyzing viral preparations is addressed, as well as the use of multi-laser nanoparticle tracking analysis (NTA) as a cost and time efficient method to measure size, count virus particles, and correlate to infectious titer.
Do you have any questions or requests? Use this form to contact our specialists.